Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Үндсэн зохиолчид: Antonio Lacquaniti (Зохиогч), Patrizio Pasqualetti (Зохиогч), Teresa Casuscelli di Tocco (Зохиогч), Susanna Campo (Зохиогч), Stefania Rovito (Зохиогч), Maurizio Bucca (Зохиогч), Antonino Ragusa (Зохиогч), Paolo Monardo (Зохиогч)
• Формат: Ном
• Хэвлэсэн: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...